Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMU3YRH)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
893990-34-6; VU 0240551; VU0240551; N-(4-Methyl-2-thiazolyl)-2-[(6-phenyl-3-pyridazinyl)thio]-acetamide; VU0240551-2-D4; N-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide; VU-0240551; n-(4-methyl-2-thiazolyl)-2-[(6-phenyl-3-pyridazinyl)thio]acetamide; VU0240551-1; N-(4-methyl-1,3-thiazol-2-yl)-2-[(6-phenylpyridazin-3-yl)thio]acetamide; C16H14N4OS2; C26H30N2O5; N-(4-methyl-1,3-thiazol-2-yl)-2-(6-phenylpyridazin-3-yl)sulfanylacetamide; AC1OHJ6T; MLS000621247; GTPL4665; CHEMBL1491962; SCHEMBL20240442; BDBM43891
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
